- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07697742
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE) (ELIMINATE)
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE): A Prospective Observational Surgical Cohort Study of Feasibility, Safety, and Radiographic Outcomes
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The primary objective of ELIMINATE, a prospective, single-centre, observational surgical cohort study, is to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging. The secondary objectives include assessment of tool-tissue forces and bleeding, residual ICH volume postoperatively, and determining the recruitment rate for patients with spontaneous lobar ICH.
The primary clinical outcome will be the proportion of enrolled patients achieving residual ICH volume <15cc on postoperative CT scan at 24 hours. Key outcomes are:
Radiographic: percent evacuation; residual volume (continuous + dichotomized). Functional: mRS at 6 months; EQ-5D-5L at 6 months; mortality at 30 and 180 days.
Intraoperative: force metrics; bleeding quantification; operative time; blood loss.
Feasibility: recruitment rate; proportion operated ≤16 hours; completeness of imaging.
Safety: symptomatic rebleeding ≤72h; postoperative deficits; infections; unplanned OR return; 30-day mortality.
A maximum of 27 adult patients will be enrolled.
Inclusion criteria:
- Adults > 18 years
- CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
- ICH volume is >30cc but <80cc as measured by (length x width x height)/2
- GCS 5-14 at presentation
- NIHSS >5
- Surgery deemed to be feasible within 16h of symptom onset
Exclusion criteria:
- Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
- Intraventricular extension estimated to involve >50% of the lateral ventricle
- Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
- Individuals presenting with GCS <5 at presentation
- Primary basal ganglia hemorrhage with lobar extension
- End-stage organ failure or life expectancy <6 months
- For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.
This study consists of one 180-day study period for each subject. Subjects will be hospitalized for care after their lobar ICH and surgical intervention according to the current standard of care. Subjects will undergo phone assessment on Day 180 by a trained assessor.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Michael D HILL, MD
- Número de telefone: 403-210-7786
- E-mail: michael.hill@ucalgary.ca
Locais de estudo
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 2T9
- Foothills Medical Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
• Adults > 18 years
- CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
- ICH volume is >30cc but <80cc as measured by (length x width x height)/2
- GCS 5-14 at presentation
- NIHSS >5
- Surgery deemed to be feasible within 16h of symptom onset
Exclusion Criteria:
• Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
- Intraventricular extension estimated to involve >50% of the lateral ventricle
- Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
- Individuals presenting with GCS <5 at presentation
- Primary basal ganglia hemorrhage with lobar extension
- End-stage organ failure or life expectancy <6 months
- For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Single cohort deisgn
Surgical evacuation of ICH using microsurgical technicque.
|
Microsurgical hematoma evacuation using microscope and neuronavigation
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recruitment rate
Prazo: Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
|
Total recruitment will be recorded each month and report as number of patients recruited per calendar month as an average for duration of the study.
The numerator will be the cumulative total number of pateints recruitment and the denominator will be the number of months elapsed since study start.
The demoninator can be a fractional number; the numerator will also be a positive integer.
|
Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Residual hematoma volume
Prazo: Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
|
Residual hematoma volume
|
Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
|
|
modified Rankin Scale Score
Prazo: at 90 days and 180 days after enrolment.
|
mRS score is an integer scale ranging from 0 to 6 (7 point interval scale).
Lower score are better and the highest score (6) implies death
|
at 90 days and 180 days after enrolment.
|
|
EuroQoL
Prazo: at 90 days and 180 days after randomization
|
EQ5D-5L is a 5 domain scale, with a 5 point Likert scale for the quesiton in each domain.
It addresses quality of life and the final score (the EQ5D Index) is adjusted by country to local norms using standardized methodology.
Higher index scores inply a higher quality of life.
|
at 90 days and 180 days after randomization
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Forceps forces
Prazo: Perioperative/peri-procedural
|
Intra-operative forceps forces during microsurgery.
These devices have haptic measurement capability and will reocrd the degree of force each time dissection or cautery are used.
Recording will be conducted during the entire operative procedure.
|
Perioperative/peri-procedural
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ELIMINATE 4.0
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .